1. ?Real life? use of sirolimus-eluting coronary stents in Germany
- Author
-
Julia C. Senges, T. Bonzel, Ralf Zahn, Ulrich Tebbe, Georg V. Sabin, Schöbel Wa, Malte Kelm, Gert Richardt, Steffen Schneider, Benny Levenson, Uwe Zeymer, Christoph A. Nienaber, and Christian W. Hamm
- Subjects
medicine.medical_specialty ,business.industry ,Cardiogenic shock ,medicine.medical_treatment ,Stent ,medicine.disease ,Surgery ,Restenosis ,Bypass surgery ,Drug-eluting stent ,Conventional PCI ,Coronary stent ,medicine ,cardiovascular diseases ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
Drugeluting stents (DES) are currently judged to be a “break-through” technology for the prevention of restenosis after percutaneous coronary interventions (PCI). However, experience is limited to randomised controlled clinical trials (RCT) in selected lesions and the currently available DES are more expensive compared to conventional “bare” stents. Therefore, actual clinical practice may be very different to RCT. We analysed the data of the German Cypher™ Registry, a nationwide registry which was initiated in parallel to the launch of the first DES, the Cypher™ sirolimus-eluting coronary stent, in April 2002. From April 2002 until March 2003, 1638 procedures at 88 hospitals were included in the German Cypher™ Registry . The mean inclusion rate per centre and month remained low (
- Published
- 2004
- Full Text
- View/download PDF